ABSTRACT
Two clonally unrelated Pseudomonas aeruginosa clinical strains, RON-1 and RON-2, were isolated in 1997 and 1998 from patients hospitalized in a suburb of Paris, France. Both isolates expressed the class B carbapenem-hydrolyzing β-lactamase VIM-2 previously identified in Marseilles in the French Riviera. In both isolates, thebla VIM-2 cassette was part of a class 1 integron that also encoded aminoglycoside-modifying enzymes. In one case, two novel aminoglycoside resistance gene cassettes,aacA29a and aacA29b, were located at the 5′ and 3′ end of the bla VIM-2 gene cassette, respectively. The aacA29a and aacA29b gene cassettes were fused upstream with a 101-bp part of the 5′ end of theqacE cassette. The deduced amino acid sequence AAC(6′)-29a protein shared 96% identity with AAC(6′)-29b but only 34% identity with the aacA7-encoded AAC(6′)-I1, the closest relative of the AAC(6′)-I family enzymes. These aminoglycoside acetyltransferases had amino acid sequences much shorter (131 amino acids) than the other AAC(6′)-I enzymes (144 to 153 amino acids). They conferred resistance to amikacin, isepamicin, kanamycin, and tobramycin but not to gentamicin, netilmicin, and sisomicin.
Among the expanded-spectrum β-lactamases in Pseudomonas aeruginosa, a few Ambler class B carbapenem-hydrolyzing β-lactamases have been characterized, including IMP-1, IMP-3, VIM-1, and VIM-2 (1, 8, 11, 12, 13,16). IMP-1-like enzymes have spread among several gram-negative rods in Japan and are found in 1.3% of the P. aeruginosaisolates there, according to a national survey conducted from 1996 to 1997 (7; H. Kurokawa, T. Yagi, N. Shibata, K. Shibayama, and Y. Arakawa, letter, Lancet 354:955, 1999). In the northern part of Italy (Verona) and in Greece, P. aeruginosaisolates have been identified that express VIM-1, which has 28% amino acid identity with IMP-1 (11, 24; G. Cornaglia, Abstr. 39th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1482, 1999). Recently the metallo-β-lactamase IMP-2, which possesses 90% amino acid identity with IMP-1, was identified from Acinetobacter baumannii, also in Verona (19). VIM-2, recently identified from P. aeruginosa COL-1 isolated in Marseilles (France) in 1996, shares 90% amino acid identity with VIM-1 (16). The VIM and IMP enzymes have a broad spectrum of hydrolysis of β-lactams that includes oxyiminocephalosporins and carbapenems.
Mobile cassettes contain genes most often mediating antibiotic resistance and a recombination site, designated 59-be (17, 18,22). The 59-be sites vary in length (57 to 141 bp) and structure, but they are all bounded by a core site (GTTRRRY) at the recombinant crossover point and an inverse core site (RYYYAAC) at the 3′ end of the inserted gene (17,18).
The four metalloenzyme genes that encode the VIM and IMP β-lactamases are each part of a gene cassette that is located in class 1 integrons (additionally in the class 3 integron for thebla IMP-1 gene cassette) (1, 11-13,19). Integrons are genetic elements capable of integrating or mobilizing individual gene cassettes by a site-specific recombination mechanism that involves a DNA integrase IntI and two types of recombination sites, attI and 59-be (4, 6, 22). The 5′ conserved segment (5′-CS) of the integron structure contains the integrase gene (intI) and the recombination siteattI1 (17, 18). The 3′-CS of class 1 integrons carries the antiseptic-resistance qacEΔ1 gene, an open reading frame of unknown function (orf5) and thesul1 gene which confers resistance to sulfonamides (17, 18).
In the course of screening for carbapenem-hydrolyzing P. aeruginosa isolates, two P. aeruginosa clinical isolates were positive for bla VIM-like genes in preliminary PCR-based analyses. Both isolates, RON-1 and RON-2, were compared to the P. aeruginosa COL-1 isolate and analyzed for their β-lactamase and integron contents. In addition to thebla VIM-2 and previously described aminoglycoside resistance gene cassettes, two cassette-integrated genes encoding novel aminoglycoside-modifying enzymes have been characterized.
MATERIALS AND METHODS
Bacterial strains, plasmids, and susceptibility testing.The bacterial strains and plasmids used in this study are listed in Table1. P. aeruginosa RON-1 and RON-2 were isolated in 1998 and 1997, respectively, at the hospital Raymond Poincaré located in a suburb of Paris. The antibiotic susceptibilities of the P. aeruginosa isolates and of theEscherichia coli recombinant strains were first determined by the disk diffusion method on Mueller-Hinton (MH) agar (Sanofi-Diagnostics Pasteur, Marnes-La-Coquette, France). The MICs of selected β-lactams and aminoglycosides were then determined by an agar dilution technique on MH agar plates with an inoculum of 104 CFU per spot (15). The activities of 2′- and 6′-N-ethylnetilmicin were studied by diffusion on MH agar at 37°C with disks containing 100 μg of antibiotic.
Bacterial strains and plasmids
Plasmid content, conjugation, and electroporation.Plasmid DNAs of P. aeruginosa RON-1 and RON-2 were extracted, analyzed, and tentatively electroporated as described previously (15). Transfer of β-lactam resistance markers fromP. aeruginosa RON-1 and RON-2 into in vitro-obtained rifampin-resistant E. coli JM109 or rifampin-resistantP. aeruginosa PU21 was performed as described before (15, 16) with transconjugant selection on Trypticase soy (TS) agar plates containing either ceftazidime (4 μg/ml) or cefotaxime (0.5 μg/ml) and rifampin (200 μg/ml).
Cloning and DNA sequencing.Whole-cell DNAs from P. aeruginosa RON-1 and RON-2 were extracted as described previously (16). PCR experiments were performed first with these DNAs as a template and primers VIMB and VIMF designed to hybridize at the 5′ and 3′ ends of the bla VIM-1 andbla VIM-2 sequences (positions 2080 to 2099 and 2671 to 2689, respectively [16]) followed by DNA sequencing on both strands. Then, fragments of whole-cell DNAs from RON-1 and RON-2 digested with BamHI (Amersham Pharmacia Biotech, Orsay, France) were ligated into the BamHI site of pBK-CMV as previously described (14). E. coli DH10B harboring recombinant plasmid DNAs were selected on kanamycin (30 μg/ml) and ceftazidime (2 μg/ml) containing TS plates and were analyzed as already described (14). The clonedBamHI fragments were sequenced on both strands with an Applied Biosystems sequencer (model ABI 373). Subsequently, aminoglycoside resistance genes from recombinant plasmid pNOR-2003 (see below) were amplified by a PCR technique (20) using primers hybridizing to the upstream region of the attI1 site (5′-CS [5′-GGCATCCAAGCAGCAAG-3′], positions 1929 to 1949; see Fig. 2) and bla VIM-2 (VIM-2B [5′-CTACTCAACGACTGAGCG-3′] hybridizing at positions 2712 to 2729; see Fig. 2) or to bla VIM-2 (VIM-2A [5′-ATGTTCAAA CTTTTGAGTAAG-3′] at positions 2029 to 2049; see Fig. 2) and to the 3′-CS (QAC-EXT [5′-AATGCGGA TGTTGCGATTAC-3′] at positions 4151 to 4170; see Fig. 2). These genes were cloned into pPCRScriptCam SK+ (Stratagene), giving recombinant plasmids pLO-1 and pLO-2, respectively. The nucleotide and the deduced protein sequences were analyzed using softwares available over the Internet (http://www.fmi.ch/biology/research_tools.htlm;http://www.ncbi.nlm.nih.gov.; andhttp: //genome.cbs.dtu.dk/services.SignalP/). Multiple nucleotide and protein sequence alignments were carried out online using the program ClustalW (http://www2.cbi.ac.uk/clustalW).
PFGE.Plugs were prepared according to the instructions of Bio-Rad. Whole-cell DNAs from P. aeruginosa COL-1, RON-1, and RON-2 isolates were digested with XbaI at 37°C overnight. Electrophoresis through a 1% agarose gel in 0.5× Tris-borate-EDTA buffer was performed using a CHEF DRII apparatus (Bio-Rad). Chromosomal fingerprints were compared by eye and assigned to pulsed-field gel electrophoresis (PFGE) types and subtypes (23).
β-Lactamase assays.Cultures of P. aeruginosaRON-1 and RON-2 were grown overnight in 10 ml of TS broth, and β-lactamase extracts were obtained and suspended in 0.5 ml of sodium phosphate buffer (0.1 M [pH 7.0]) (16). Hydrolysis of imipenem (100 μM) was determined quantitatively in a Pharmacia ULTROSPEC 2000 spectrophotometer as described previously (16). The protein content was measured using the Bio-Rad DC Protein assay.
RESULTS
Characterization of the carbapenem-hydrolyzing β-lactamase ofP. aeruginosa RON-1 and RON-2 and their antibiotic resistance patterns. P. aeruginosa RON-1 was a clinical isolate from recurrent urinary tract infections of a tetraplegic patient who had recurrent renal lithiasis. He had been treated by several courses of antibiotics including aztreonam and fosfomycin. His past clinical history also reported urinary infections due to various enterobacterial isolates that were treated with ciprofloxacin or amikacin but not with carbapenems. P. aeruginosa RON-2 was isolated from a urinary tract infection of a hospitalized patient and, like P. aeruginosa COL-1, had been isolated prior to the isolation date (February 1997) of thebla VIM-1-containing P. aeruginosaVR-143/97 in Verona, Italy (12). Patients infected withP. aeruginosa RON-1 or RON-2 did not have a history of travel to or hospitalization in Italy or Marseilles, wherebla VIM-1 and bla VIM-2, respectively, had been first identified. The presence of a carbapenem-hydrolyzing β-lactamase was suspected in P. aeruginosa RON-1 and RON-2 as a result of routine antibiotic susceptibility testing that showed that both strains were resistant to ceftazidime and imipenem but remained susceptible to the monobactam aztreonam. Determination of the MICs of β-lactams for these P. aeruginosa isolates confirmed these results (Table2). No other P. aeruginosaisolate was identified harboring a similar β-lactam resistance profile in the same hospital from January 1997 to May 2000. Additionally, P. aeruginosa RON-1 and RON-2 were resistant to multiple aminoglycosides, tetracycline, chloramphenicol, fosfomycin, and fluoroquinolones and were of intermediate susceptibility to rifampin.
MICs of β-lactams for VIM-2-possessing P. aeruginosa clinical strains, E. coli DH10B harboring recombinant plasmids pNOR-2002 and pNOR-2003, and reference strainE. coli DH10B
As assessed by their ability to hydrolyze imipenem, P. aeruginosa RON-1 and RON-2 produced a carbapenem-hydrolyzing β-lactamase (specific activity of 22 and 45 mU per mg of proteins, respectively). PCRs performed with whole-cell DNAs of P. aeruginosa RON-1 and RON-2 as templates followed by DNA sequencing revealed that both isolates possessed the samebla VIM-2 gene.
PFGE analysis showed that P. aeruginosa COL-1, RON-1, and RON-2 had distinguishable profiles (data not shown), although RON-1 and RON-2 were isolated from the same hospital.
The β-lactam resistance markers were not transferred by conjugation from P. aeruginosa RON-1 or RON-2 either to rifampin-resistant E. coli JM109 or to rifampin-resistantP. aeruginosa PU21. Analysis of the plasmid DNAs of P. aeruginosa RON-1 and RON-2 did not reveal evidence for any plasmid; electroporation experiments also failed. Thebla VIM-2 gene was therefore likely chromosomally located in these isolates.
Structure of the bla VIM-2cassette-integrated class 1 integron In58.A recombinant plasmid pNOR-2002 was retained as a result of cloning of RON-1 DNA. E. coli DH10B harboring pNOR-2002 gave the same β-lactam resistance profile as observed after cloning of thebla VIM-2 gene from P. aeruginosaCOL-1 and its expression in E. coli (Table 2) (16). As reported, the carbapenem resistance was not expressed at a high level in E. coli (Table 2) (12, 16). E. coli JM109 (pNOR-2002) was resistant to amikacin, kanamycin, tobramycin, and sulfonamides while E. coli JM109 (pBK-CMV) was resistant to kanamycin and neomycin (data not shown).
Sequence analysis of the 5,648-bp BamHI insert in pNOR-2002 revealed the structure of a class 1 integron, designated In58, with 5′-CS and 3′-CS ends (Fig. 1). The 5′-CS contained the integrase gene intI1 and the attI1recombination site. Within the integrase gene, a weak promoter Pc (−35 [TGGACA]; −10 [TAAGCT]) was identified (3). At the 3′-CS end, theqacEΔ1 disinfectant determinant gene and thesuI1 sulfonamide resistance gene were identified as in most class 1 integrons (18). Between its 5′-CS and 3′-CS ends, In58 contained four gene cassettes containing antibiotic resistance genes (Fig. 1). Just downstream of the 5′-CS, an aacA7 gene cassette encoding an AAC(6′)-I1 aminoglycoside acetyltransferase was identified as in Enterobacter aerogenes (Fig.2) (2). Its 59-be differed by only three nucleotide substitutions out of 112 (GenBank accession no. U13880). The bla VIM-2 gene cassette was inserted as the second position and was identical to that inserted in In56 in P. aeruginosa COL-1 (16). The third cassette contained an aacC1 gene encoding a 3-N-aminoglycoside acetyltransferase AAC(3)-I (9). This gene differed by 3 nucleotide changes out of 465 from the gene from Serratia marcescens. Only one mutation altered the amino acid sequence with a substitution of a proline for an alanine (GenBank accession no. S68049). The 59-be differed by only two mismatchs out of 108 bp (GenBank accession no.S68049). The fourth cassette contained an aacA4 gene cassette identical to that reported from Pseudomonas fluorescens (GenBank accession no. AAA25685 [10]). It encodes an aminoglycoside 6′-N-acetyltransferase [AAC(6′)-Ib′] that confers resistance to gentamicin, netilmicin, and tobramycin but does not modify amikacin.
Comparative structures of the class 1 integrons In58 and In59 that contain the bla VIM-2 gene cassette from P. aeruginosa RON-1 and RON-2 clinical isolates, respectively. The intI1 integrase gene, which encodes the integrase, is contained in the 5′-CS, and the 3′-CS found downstream of the integrated gene cassette includes the sulfonamide resistance genesul1 and the disinfectant resistance determinantqacEΔ1. Inserted genes are indicated by boxes, and the arrows indicate their transcriptional orientation. The 59-be's are represented by black circles and the attI1 recombination sites by white circles.
Nucleotide sequence of a 5,061-bp BamHI fragment of pNOR-2003 containing the VIM-2 coding sequence and part of integron In59. The start codons of the ORFs are indicated by horizontal arrows, and the deduced amino acid sequences are reported below the nucleotide sequence. Stop codons for each ORF are indicated by asterisks. Dashes in the nucleotide sequence indicate where the reported sequence was identical to published sequences. The −35 and −10 sequences of promoters Pc and putativeqacE/qacEΔ1 are indicated. The conserved core and inverse core sites located at each cassette boundary are boxed, and the composite 59-be's are italicized. The cassette boundaries are indicated by vertical arrows as well as the putative fusion points of the 5′ end of part of the qacE cassette to theaacA29 gene cassettes. The attI1 site is underlined with a dashed line.
Novel aminoglycoside resistance genes and structure of thebla VIM-2 cassette-integrated class 1 integron In59.A recombinant plasmid pNOR-2003 was retained as a result of cloning RON-2 DNA. E. coli DH10B (pNOR-2003) gave the same β-lactam resistance profile as observed for E. coli DH10B (pNOR-2002) (Table 2).
Sequence analysis of the cloned 5,061-bp BamHI fragment of pNOR-2003 showed another class 1 integron, designated In59. It contained 5′-CS and 3′-CS structures with the same Pcpromoter as in In58 located downstream from the integrase gene,intI (Fig. 1 and 2). The bla VIM-2gene cassette was identical to those found in In56 and In58.
The bla VIM-2 gene cassette was flanked by two novel aminoglycoside acetyltransferase cassette-associated genes, namedaacA29a and aacA29b. AAC(6′)-29a shared 96% amino acid identity with AAC(6′)-29b, differing in only four amino acids located near the center of the protein (Fig.3). AAC(6′)-29a and AAC(6′)-29b shared 35 and 34% identity with the most closely related 6′-N-aminoglycoside acetyltransferaseaacA7-encoded AAC(6′)-I1, respectively. Recombinant plasmids that contained either aacA29a (pLO-1) or aacA29b(pLO-2) genes were used to transform E. coli JM109. E. coli JM109 harboring pLO-1 or pLO-2 had the same resistance profile, including resistance or a decreased susceptibility to amikacin, dibekacin, isepamicin, tobramycin, and kanamycin and susceptibility to gentamicin, netilmicin, and sisomicin (Table3). E. coli JM109 (pNOR-2003) expressing aacA29a and aacA29b genes conferred a level of resistance to aminoglycosides similar to or higher than that observed for E. coli JM109 (pLO-1) or E. coliJM109 (pLO-2) (Table 3).
Comparisons of the deduced amino acid sequences of AAC(6′)-29a and AAC(6′)-29b proteins with those of the most closely related aminoglycoside acetyltransferases. Amino acid differences between AAC(6′)-29a and AAC(6′)-29b appear in grey. Identical amino acids in at least 17 sequences are indicated by asterisks; conserved amino acid substitutions are indicated by dots according to the following exchange groups: A, G, P, S, and T; H, K, and R; F, W, and Y; D, E, N, and Q; and I, L, M, and V. Boxed motifs at the carboxy terminal end of the proteins are conserved in most of the enzymes and are absent in AAC(6′)-29 proteins.
MICs of various aminoglycosides for P. aeruginosa RON-2, E. coli JM109 harboring recombinant plasmids pLO-1 and pLO-2 containing aacA29a andaacA29b genes, respectively, and reference strain E. coli JM109
Disk susceptibility tests indicated that both transformants had a 6′-N-acetyltransferase of type I [AAC(6′)-I] resistance phenotype. Since 2′- and 6′-N-ethylnetilmicin exhibit similar levels of potency against aminoglycoside-susceptible strains, a significant decrease of 2′-N-ethylnetilmicin activity compared with that of 6′-N-ethylnetilmicin results in protection at the modifying site and can be taken as evidence for production of a 6′-N-acetyltransferase (21). The resistance to amikacin and susceptibility to gentamicin is characteristic of the AAC(6′)-I type. The aacA29aminoglycoside resistance genes accounted for part of the broad-spectrum aminoglycoside resistance observed for P. aeruginosa RON-2 (Table 3).
These aacA29a and aacA29b acetyltransferase gene cassettes possessed similar 59-be's made of 112 and 105 bp, respectively, that varied from one to the other by 17 bp. TheaacA29a and aacA29b gene cassettes consisted of the region extending from position 1387 to 1898 and from position 2909 to 3413, respectively (Fig. 2). Interestingly, both the 59-be of theaacA29a gene cassette and that of the aacA29bgene cassette were related to the 111-bp-long 59-be of theaacA7 cassette, differing by 31 and 36 bp, respectively (2). A fusion of the first 101 bp of the qacEcassette (5) to the upstream part of theaacA29a and aacA29b gene cassettes generated two novel cassettes extending from positions 1286 to 1898 and from 2808 to 3413, respectively (Fig. 2).
DISCUSSION
P. aeruginosa RON-1 and RON-2 were the second and third P. aeruginosa unrelated isolates in France that produced a carbapenem-hydrolyzing β-lactamase. As identified previously in P. aeruginosa COL-1 isolated from another French region, an identical bla VIM-2 gene was found. However, the plasmid location of bla VIM-2found in P. aeruginosa COL-1 (as for thebla VIM-1 location in P. aeruginosaisolate VR-143/97 [12]) was not detected in P. aeruginosa RON-1 and RON-2. In all cases thebla VIM-2 gene cassettes were identical. Thus, spread of the bla VIM-2 gene cassette has already occurred in several class 1 integrons in P. aeruginosa in France. This spread may have occurred also in other gram-negative species (Enterobacteriaceae) in which carbapenem resistance is not expressed at a high level (8, 12, 16). Additionally, the origin of bla VIM-1 andbla VIM-2 remains unknown since these genes are not related to any known naturally occurring class B carbapenem-hydrolyzing β-lactamase gene.
Contrary to In56 from P. aeruginosa COL-1 that contains a single bla VIM-2 gene cassette, In58 and In59 from P. aeruginosa RON-1 and RON-2 contain the samebla VIM-2 gene cassette and additional gene cassettes containing multiple aminoglycosideN-acetyltransferase genes. Characterization of In59 revealed interesting features. It included two novel aacA29aminoglycoside resistance genes showing a G+C content of 55.6%, a value suggesting that they may not have originated from P. aeruginosa, thus further underlining the mobility of gene cassettes. The presence of a 101-bp sequence of a qacEcassette upstream of each aacA29 cassette may have resulted from recombination at the sequence GATATAT of theqacE cassette and the core site of the ancestralaacA29 cassette. The fact that this event took place between two nonhomologous recombining sites suggests a RecA-independent process such as an integrase-mediated process (6). The sequence located upstream of the aacA29 genes that contain a weak promoter sequence for transcription of qacE andsul1 genes (5) may also direct the transcription of the aacA29 genes.
Comparison of AAC(6′)-29a and AAC(6′)-29b with related members of the 6′-N-aminoglycoside acetyltransferases revealed the presence of a large number of completely conserved residues, but an obvious truncation of their carboxyl termini, resulting in shorter proteins of 131 amino acid residues, as opposed to the 144 to 153 residues of all other members (Fig. 3). The AAC(6′)-29 sequences did not contain the highly conserved motif ETERVVYF found in most members of the 6′-N-aminoglycoside acetyltransferase family (Fig. 3). SinceE. coli JM109 expressing each of the AAC(6′)-29 proteins was resistant to amikacin, dibekacin, isepamicin, kanamycin, and tobramycin and remained susceptible to gentamicin, netilmicin, and sisomicin, the AAC(6′)-29 proteins conferred a modified AAC(6′)-I phenotype. Further experiments need to be performed to establish if the truncation of the carboxyl termini is involved in alteration of the substrate specificity of AAC(6′)-29 proteins.
Finally, the simultaneous presence of broad-spectrum β-lactamase and multiple aminoglycoside acetyltransferase gene cassettes in class 1 integrons raises the question of whether the clinical use of either broad-spectrum β-lactams or broad-spectrum aminoglycosides may increase a selective pressure for such multiply resistant isolates and for episomal transfer of these integrons into a susceptible host. Future cure of P. aeruginosa infections may fail, as exemplified for infected patients hospitalized in some intensive care units in Japan, and now in Europe (7, 12,16).
ACKNOWLEDGMENTS
This work was funded by the Ministère de l'Education Nationale et de la Recherche (grant UPRES-JE 2227), UniversitéParis XI, Paris, France.
We thank T. Naas and J. Blanchard for helpful discussions.
FOOTNOTES
- Received 19 May 2000.
- Returned for modification 24 August 2000.
- Accepted 17 November 2000.
- Copyright © 2001 American Society for Microbiology
